Hepatitis Treatment News : Viral Enzyme Assay Opens the Door for New Hep B Therapies and a Possible Cure
A Smart + Strong Site
Subscribe to:
Hep Magazine In Bulk
Hep Newsletter
Join Us:

Back to home » Hepatitis Treatment News » February 2013


February 19, 2013

Viral Enzyme Assay Opens the Door for New Hep B Therapies and a Possible Cure

In a major breakthrough, researchers have identified compounds that succeed in blocking an enzyme critical to hepatitis B virus (HBV) production, possibly opening the door for the development of a new treatment class that, when combined with currently available drugs, might even eradicate the virus. Publishing their results in PLOS Pathogens, researchers at Saint Louis University, the University of Missouri and the University of Pittsburgh built on past success in developing an assay that identified the enzyme ribonuclease H (RNAseH).

Currently, the five most commonly used HBV drugs all target a DNA polymerase; RNAseH is a second vital element of the hep B life cycle and a prime potential drug target. The researchers developed 21 potential RNAseH inhibitors, which were based on antagonists of RNAseH and integrase enzymes in HIV. A total of 12 of these agents inhibited hep B RNAseH according to enzymatic assays, and one in cell-based assays.

The investigators call their work a proof of principle for this potential new class of HBV agents and are now setting their sights on studying the RNAseH enzyme in a variety of hep B genotypes.

To read the Saint Louis University release, click here.

To read the study, click here

Search: hepatitis B, HBV, virus, new compound, viral enzyme assay, therapy, PLOS Pathogens, Saint Louis University, University of Missouri, University of Pittsburgh, ribonuclease H, RNAseH.

Scroll down to comment on this story. Click here to visit the Hep Forums and ask questions about this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The Hep team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (1 total)

[Go to top]

Quick Links
Current Issue
Hep TV
Services Directory
Conference News
Top Stories
Treatment News
Hep Exclusives
All About Hepatitis
• Hepatitis A
• Hepatitis B
• Hepatitis C
HCV/HIV Coinfection
Help Paying For Meds
Clinical Trials
Tell us what you think
Should Medicaid limit access to new hep C drugs?

Hepatitis C Reader Survey
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.